AD-LIB.IO
12.5.2021 09:02:04 CEST | Business Wire | Press release
Ad-Lib.io , the next-generation Creative Management Platform for marketers at the world’s largest brands, today announced that it has been certified as a Google Marketing Platform (GMP) Partner in Spain, bringing Ad-Lib.io its sixth creative certification as it continues to extend its footprint across the globe.
The GMP Creative Certification in Spain affirms that Ad-Lib.io has demonstrated the ability to work within Google’s best practices and technology, and reinforces that its next-generation Creative Management Platform upholds high standards of service for creative design and process management. The certification reaffirms Ad-Lib.io’s successful client track record and its expertise across key capabilities including coding, asset delivery, and client services. The certification gives Ad-Lib.io , early access to product releases and announcements, and to a variety of other Google program resources.
“As the advertising industry emerges from a difficult year, advertisers are pushed to make their creative workflow more efficient while ensuring their ads stand out and perform well,” said Adit Abhyankar, CEO of Ad-Lib.io. “As a Google Marketing Platform Partner certified on the Creative tools, Ad-Lib.io offers advertisers in Spain on Google’s tech stack, the ability to easily and quickly build and activate content at scale, across formats and channels. Ad-Lib.io has been a trusted Google Partner since our founding in 2017 and we will continue to lead the way for advertisers that seek to produce and optimize relevant creative at scale.”
“As Google and its customers continue to find new ways to work together, partners like Ad-Lib.io are an important part of our ecosystem as they got certified.” according to Jose Maria Perez Sastre, Partnerships Manager at Google. “We are pleased that Ad-Lib.io continues to grow its presence and customers in Spain. We have seen great success already working together on clients in the region and we look forward to the continuing partnership in Spain and in other markets around the globe.”
This milestone strengthens Ad-Lib.io’s capability for customers working with the Google Marketing Platform in Spain and globally, as marketers seek solution providers that operate in the markets they serve. One partner with multi-region certifications, Ad-Lib.io is also a GMP Creative Partner in the United Kingdom, the United States, Dubai, Australia and Singapore.
“I'm very excited by the launch of another Google-certified market in Spain!” said Oli Marlow Thomas, founder of Ad-Lib.io. “This accompanies the awesome news that Ad-Lib.io DE is now up and running with former Googler Felix Derkum leading the charge. Ad-Lib.io is pushing into all parts of Europe.”
For more information about Ad-Lib.io, please visit: https://www.ad-lib.io/ .
About Ad-Lib.io
Ad-Lib.io provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-Lib.io’s customers which include 10 of the top 30 global brands. The venture-backed company -- recognized as a 2021 Start Up of the Year by Campaign Magazine -- was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution. Ad-Lib.io is headquartered in London, UK with offices in North America, Asia, Australia, Europe and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
